GSK licenses TB vaccine to Bill and Melinda Gates Institute

GlaxoSmithKline has licensed its potential tuberculosis vaccine to the Bill and Melinda Gates Medical Research Institute, saying this is the best way for it to be developed for low-income c

Quench targets lupus and rare diseases with R&D into new dru...

Quench Bio has emerged from stealth mode with $50 million of committed funding, bidding to be the first company to target Gasdermin D (GSDMD) in inflammatory disease indications poorly serv

Ipsen craters as pricey rare disease drug is put on hold aga...

Big pharma joins hunt for coronavirus vaccine as outbreak es...

Big pharma has joined the hunt for a vaccine for the deadly coronavirus outbreak that is beginning to spread around the world from its origins in China.

Roche edges closer to SMA market as risdiplam hits target in...

Roche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the rare muscle wasting disease spinal muscular atrophy (SMA) after support

AstraZeneca commits to being carbon negative by 2030

AstraZeneca has announced its ambition to have zero carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon negative by 2030, bringing forward decarbon